Video

Titilope Fasipe, MD, PhD: Plenary Speaker at NORD Summit

Author(s):

As the opening plenary speaker at the National Organization for Rare Disease summit, Dr. Fasipe shares from her unique perspective as doctor and patient of sickle cell disease.

Titilope Fasipe, MD, PhD, Assistant Professor of Pediatric Hematology-Oncology, Baylor College of Medicine, was invited to be the opening plenary speaker at the National Organization for Rare Disease (NORD) summit.

Traditionally, the position of the opening plenary speaker has gone to individuals who shared personal experiences with a rare disease. Fasipe has a unique perspective as a patient and a doctor of sickle cell disease.

In her talk, Fasipe mentions the importance of successful partnerships. It's not uncommon for a patient of rare disease to feel isolated or alone in their experience.

"There's not enough awareness about them in the community," Fasipe said about rare diseases, "even the medical community."

When people or organizations partner together, it can make all the difference. Whether it's healthcare institutions, government agencies, or even local community based organizations, there's strength in working together.

"At the end of the day the goal is to bring exposure and light to that disease and the most important part is to improve the outcome, the quality of life of the people who have that disease," Fasipe explained. "Just because your disease affects less people in the country does not make it less important."

Related Videos
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
Developing Risk Assessment Tools for Viruses in School
© 2024 MJH Life Sciences

All rights reserved.